

02.11.2018

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code : CAPLIPOINT.

By NEAPS

Dear Sirs,

SUB: OUTCOME OF THE BOARD MEETING

The Board of Directors of the Company at their meeting held today approved the Un-audited Financial Results (Consolidated & Standalone) for the quarter/half year ended September 30, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herewith enclose:

1. Un-audited Financial Results (Consolidated & Standalone) for the quarter/half year ended September 30, 2018.
2. Limited Review Report (Consolidated & Standalone) for the above Un-audited Financial Results
3. Press release on the above Un-audited Financial Results

The Board Meeting commenced at 10.25 AM and concluded at 12.30 PM

Thanking You,

Yours Faithfully,
For Caplin Point Laboratories Limited



Company Secretary

Enclosure: As above

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE THREE MONTHS AND HAIF YEAR ENDED 30th SEPTEMBER 2018

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

Particulars	Three Months ended			Half year ended		Financial Year Ended
	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
	(1)	(2)	(3)	(4)	(5)	(6)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	INR in lakhs					
Income:						
I Revenue from operations	15,586.30	14,645.99	13,131.13	30,232.29	25,482.32	53,984.20
II Other income	701.32	160.93	357.69	862.24	743.90	1,266.52
III Total Income (I+II)	16,287.61	14,806.92	13,488.82	31,094.53	26,226.22	55,250.72
IV Expenses:						
a. Cost of materials consumed	2,300.15	2,364.99	2,405.23	4,665.14	4,430.47	9,021.63
b. Purchase of traded goods	4,789.41	4,041.29	3,404.91	8,830.70	6,686.05	15,035.10
c. Changes in inventories of finished goods, stock in trade and work in progress	(62.61)	2.99	(99.38)	(59.62)	(54.96)	(238.77)
d. Employee benefit expenses	1,146.12	1,152.40	1,016.15	2,298.52	1,913.57	3,914.27
e. Finance cost	1.95	1.22	1.69	3.17	3.30	6.12
f. Depreciation & Amortisation Expenses	557.84	545.33	445.01	1,103.17	829.46	1,899.50
g. Other Expenses	1,834.71	1,781.28	1,467.95	3,615.99	2,981.01	6,775.04
h. Total Expenses	10,567.58	9,889.50	8,641.57	20,457.07	16,788.89	36,412.89
V Profit before exceptional items and Tax (III-IV)	5,720.04	4,917.42	4,847.25	10,637.46	9,437.33	18,837.83
VI Exceptional items	-	-	-	-	-	-
VII Profit Before Tax (V-VI)	5,720.04	4,917.42	4,847.25	10,637.46	9,437.33	18,837.83
VIII Tax Expenses	-	-	-	-	-	-
(1) Current Tax	1,146.66	948.55	1,232.32	2,095.21	2,115.95	4,054.91
(2) Deferred Tax	223.61	229.46	61.25	453.07	135.24	319.42
Total Tax Expenses	1,370.27	1,178.01	1,293.57	2,548.28	2,251.19	4,374.33
IX Net Profit for the period (VII - VIII)	4,349.78	3,739.41	3,553.68	8,089.19	7,186.14	14,463.50
X Other Comprehensive Income - Net of Income Tax	-	-	-	-	-	-
A. Items that will not be re-classified to profit or loss	-	-	-	-	-	-
i) Remeasurements of Defined Benefit Plan	22.84	14.05	4.19	36.89	8.32	76.60
B. Items that will be re-classified to profit or loss	-	-	-	-	-	-
i) Exchange difference in translating the financial statements of foreign operations	308.86	(10.42)	-	298.44	-	-
XI Total Comprehensive Income For The Period (IX + X)	4,681.48	3,743.04	3,557.87	8,424.52	7,198.82	14,540.10
XII Profit attributable to:						
Owners of the Company	4,685.97	3,742.90	3,557.17	8,428.88	7,190.50	14,478.77
Non- controlling interests	(0.87)	(3.49)	(3.49)	(4.36)	(4.36)	(15.27)
XIII Total Comprehensive Income For The Period attributable to	4,685.11	3,739.41	3,553.68	8,424.52	7,186.14	14,463.50
Owners of the Company	4,692.04	3,746.53	3,561.36	8,438.58	7,203.18	14,555.37
Non- controlling interests	(0.87)	(3.49)	(3.49)	(4.36)	(4.36)	(15.27)
XIV Paid up Equity Share Capital (Face value of share of Rs 2/- each)	1,512.07	1,512.07	1,511.53	1,512.07	1,511.53	1,512.07
XV Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year						34,871.08
XVI Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share						
(a) Basic (in Rupees)	6.21	4.95	4.71	11.16	9.53	19.26
(b) Diluted (in Rupees)	6.18	4.92	4.69	11.11	9.48	19.16



CAPLIN POINT LABORATORIES LIMITED
CONSOLIDATED BALANCE SHEET AS AT SEPTEMBER 30, 2018
(All amounts are in ₹ lakhs except share data unless otherwise stated)

Particulars	As at September 30, 2018	As at March 31, 2018
ASSETS		
(1) Non-Current Assets		
(a) Property, Plant and Equipment	17,820.43	16,741.82
(b) Capital work-in-progress	1,489.87	1,529.12
(c) Other Intangible assets	237.57	206.51
(d) Financial Assets		
(i) Investments (Refer Note 4)	4,386.99	4,144.88
(ii) Loans	1,074.33	1,123.19
Sub-total-Non current assets	25,009.19	23,745.52
(2) Current Assets		
(a) Inventories	2,668.17	2,845.56
(b) Financial Assets		
(i) Investments	6,050.05	522.26
(ii) Trade Receivables	14,852.60	12,588.15
(iii) Cash and Cash equivalents	818.60	6,237.66
(iv) Bank balances other than (iii) above	3,756.44	1,690.20
(iv) Loans (Refer Note 5)	5,769.83	2,384.61
(d) Other Current Assets	74.40	31.06
Sub-total-Current assets	33,990.09	26,299.50
Total	58,999.28	50,045.02
Equity and Liabilities		
(1) Equity		
Equity Share capital	1,512.07	1,512.07
Other Equity	42,007.52	34,871.08
Equity attributable to shareholders of the company	43,519.59	36,383.15
Non controlling interest	4.68	9.04
Sub-total-Total Equity	43,524.27	36,392.19
(2) Liabilities		
(A) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	44.82	32.19
(ii) Other financial liabilities	-	-
(b) Deferred Tax Liabilities (Net)	2,669.14	2,216.07
(c) Other Long term liabilities	527.23	537.61
(d) Provisions	-	-
Sub-total-Non current liabilities	3,241.19	2,785.87
(B) Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables	9,549.14	9,422.53
(ii) Other Current Liabilities	2,334.13	1,266.07
(b) Provisions	350.55	178.36
Sub-total-Current liabilities	12,233.82	10,866.96
Total	58,999.28	50,045.02



Indhan

Notes :

- 1) This statement has been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 2) The above results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meeting held on 2nd November 2018.
- 3) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra
- 4) The liquidity position of the company as on 30th September 2018 is tabulated as below:-
Cash & Cash Equivalent *

	Rs in Lakhs
i. Mutual Fund - Classified under long term investment	4,353.58
ii. Mutual Fund - Classified under Short term	6,050.05
iii. Cash & Cash equivalent	818.60
iv. Deposits - Classified under other bank balance	2,038.81
Total	13,261.04

* Dividend bank account balance of Rs 1717.63 lakhs has not been considered for determining Cash & Cash Equivalent as same is earmarked towards dividend payable included in other current liabilities.
- 5) Loans reported under current assets includes Rs 3529.53 lakhs paid as advance to Channel partner in El Salvador for acquiring their assets by Caplin Point's step down subsidiary Caplin El Salvador S.A.de .
- 6) The statutory auditors have carried out a limited review of the consolidated results for the quarter ended 30th September 2018.
- 7) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai

Date: 2nd November 2018


Dr Sridhar Ganesan
Managing Director




CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE THREE MONTHS AND HAIF YEAR ENDED 30th SEPTEMBER 2018

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

Particulars	Three Months Ended			Half year ended		Financial Year Ended	
	30.09.2018 (1)	30.06.2018 (2)	30.09.2017 (3)	30.09.2018 (4)	30.09.2017 (5)	31.03.2018 (6)	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	INR In Lakhs						
Income:							
I Revenue from operations	13,123.80	12,516.28	10,340.64	25,640.08	20,529.84	42,657.39	
II Dividend from subsidiary (Refer Note 3)	-	1,648.24	1,139.50	1,648.24	1,139.50	1,139.50	
III Other income Including dividend/share of profit from subsidiary/LLP	666.70	157.25	274.23	823.95	660.44	1,191.83	
IV Total Income (I+II+III)	13,790.50	14,321.77	11,754.37	28,112.27	22,329.78	44,988.72	
V Expenses:							
a. Cost of materials consumed	2,300.15	2,364.99	2405.24	4665.14	4430.48	9,021.63	
b. Purchase of traded goods	3,745.97	3,203.10	2008.28	6949.07	4328.15	9,228.22	
c. Changes in inventories of finished goods, stock in trade and work in progress	(62.61)	2.99	(99.38)	(59.62)	(54.96)	(238.77)	
d. Employee benefit expenses	1,128.67	1,145.92	1016.15	2,274.59	1913.57	3,882.04	
e. Finance cost	1.95	1.22	1.69	3.17	3.3	6.12	
f. Depreciation & Amortisation Expenses	556.58	545.23	444.45	1,101.81	828.90	1,898.78	
g. Other Expenses	1,787.83	1,744.06	1409.38	3,531.89	2914.42	6,585.40	
h. Total Expenses	9,458.54	9,007.51	7,185.81	18,466.05	14,363.86	30,383.42	
VI Profit before exceptional items and Tax (IV-V)	4,331.96	5,314.26	4,568.56	9,646.22	7,965.92	14,605.30	
VII Exceptional items	-	-	-	-	-	-	
VIII Profit Before Tax (V-VI)	4,331.96	5,314.26	4,568.56	9,646.22	7,965.92	14,605.30	
IX Tax Expenses							
(1) Current Tax	1,146.30	948.55	1,232.32	2,094.85	2,115.95	4,054.79	
(2) Deferred Tax	223.61	229.46	61.25	453.07	135.24	319.42	
Total Tax Expenses	1,369.91	1,178.01	1,293.57	2,547.92	2,251.19	4,374.21	
X Net Profit for the period (VII-VIII)	2,962.05	4,136.25	3,274.99	7,098.30	5,714.73	10,231.09	
XI Other Comprehensive Income/ (Loss) - Net of Income Tax							
A. Items that will not be re-classified to profit or loss							
i) Remeasurements of Defined Benefit Plan	22.84	14.05	4.19	36.89	8.32	76.60	
XII Total Comprehensive Income For The Period (IX+X)	2,984.89	4,150.30	3,279.18	7,135.19	5,723.05	10,307.69	
XIII Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	1,512.07	1,512.07	1,511.53	1,512.07	1,511.53	1,512.07	
XIV Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year						28,048.36	
XV Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share							
(a) Basic (in Rupees)	3.95	5.47	4.34	9.44	7.57	13.64	
(b) Diluted (in Rupees)	3.93	5.45	4.32	9.39	7.54	13.57	

Indhan



Notes :

- 1) This statement has been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 2) The above results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meeting held on 2nd November 2018.
- 3) The Other income for the three months period ended 30 June 2018 includes a dividend income of Rs 1648.03 lakhs (Nil for the three months period ended 30th September 2018) from 100% foreign subsidiary in Hong Kong .As such the Profits and EPS for these quarters are not directly comparable .
- 4) The liquidity position of the company as on 30th September 2018 is tabulated as below:-

Cash & Cash Equivalent *	Rs in Lakhs
i. Mutual Fund - Classified under long term investment	4,353.58
ii. Mutual Fund - Classified under Short term	6,050.05
iii. Cash & Cash equivalent	141.35
iv. Deposits - Classified under other bank balance	1,997.76
Total	12,542.74

* Dividend bank account balance of Rs 1717.63 lakhs has not been considered for determining Cash & Cash Equivalent as same is earmarked towards dividend payable

- 5) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 6) The statutory auditors have carried out a limited review of the stand alone results for the quarter ended 30th September 2018.
- 7) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai
Date: 2nd November 2018



Dr Sridhar Ganesan
Managing Director



CAPLIN POINT LABORATORIES LIMITED

BALANCE SHEET As at September 30, 2018

(All amounts are in ₹ lakhs except share data unless otherwise stated)

Particulars	As at September 30, 2018	As at March 31, 2018
ASSETS		
(1) Non-Current Assets		
(a) Property, plant and equipment	17,817.24	16,740.16
(b) Capital work-in-progress	1,489.87	1,529.12
(c) Other intangible assets	180.29	191.74
(d) Financial assets		
(i) Investments (Refer Note 4)	4,594.28	4,298.83
(ii) Loans	1,061.20	1,110.91
Sub-total-Non current assets	25,142.88	23,870.76
(2) Current Assets		
(a) Inventories	2,668.17	2,845.56
(b) Financial assets		
(i) Investments	6,050.05	522.26
(ii) Trade receivables	9,438.74	8,635.31
(iii) Cash and cash equivalents	141.35	1,139.31
(iv) Bank balances other than (iii) above	3,715.39	1,689.15
(iv) Loans	2,228.44	2,346.87
(d) Other current assets	74.41	31.01
Sub-total-Current assets	24,316.55	17,209.47
Total	49,459.43	41,080.23
EQUITY AND LAIBILITIES		
(1) Equity		
Equity share capital	1,512.07	1,512.07
Other equity	33,896.12	28,048.36
Sub-total-Total Equity	35,408.19	29,560.43
(2) Liabilities		
(A) Non-Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	44.82	32.19
(ii) Other financial liabilities	-	-
(b) Deferred tax liabilities (Net)	2,669.14	2,216.07
(c) Other long term liabilities	527.23	537.61
(d) Provisions	-	-
Sub-total-Non current liabilities	3,241.19	2,785.87
(B) Current Liabilities		
(a) Financial liabilities		
(i) Trade payables	8,172.59	7,289.50
(ii) Other current liabilities	2,334.13	1,266.07
(b) Provisions	303.33	178.36
Sub-total-Current liabilities	10,810.05	8,733.93
Total	49,459.43	41,080.23



Signature



CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No.43
Vijayaraghava Road, T.Nagar, Chennai - 600 017 India.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

Limited Review Report on Quarterly/ Half yearly Consolidated Financials Results of Caplin Point Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015

To
The Board of Directors
Caplin point Laboratories Limited

We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Caplin Point Laboratories Limited** ("the company"), its subsidiaries (the company, its subsidiaries constitute "the group") for the quarter and six months ended 30th September 2018, attached herewith, being submitted by the company pursuant to the requirements of regulations 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations,2015..

This statement is the responsibility of the Company's management and has been approved by the Board of Directors in their meeting held on 2th November 2018. Our responsibility is to issue report on these financials statements based on our review.

Scope of Review

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered accounts of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statements includes the results of the following entities:

1. Argus Salud Pharma LLP
2. Caplin Point Far East Limited
3. Caplin Point Laboratories Colombia SAS
4. Caplin Elsalvador S.A.de





CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No.43
Vijayaraghava Road, T.Nagar, Chennai - 600 017 India.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e., Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies act, 2013 read with relevant rules thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular dated 05 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for M/s CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
Firm Registration No: 004915S/S200036



Place : Chennai
Date : 02/11/2018

K.PARTHASARATHY
Partner
Membership No: 018394



CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No.43
Vijayaraghava Road, T.Nagar, Chennai - 600 017 India.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

Limited Review Report on Quarterly/ Half yearly Standalone Financials Results of Caplin Point Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015

To
The Board of Directors
Caplin point Laboratories Limited

We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of **Caplin Point Laboratories Limited** for the quarter and six months ended 30th September 2018, attached herewith, being submitted by the company pursuant of the requirements of regulations 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations,2015.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors in their meeting held on 2th November 2018. Our responsibility is to issue report on these financials statements based on our review

Scope of Review

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered accounts of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No.43
Vijayaraghava Road, T.Nagar, Chennai - 600 017 India.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e., Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies act, 2013 read with relevant rules thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular dated 05 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for M/s CNGSN &
ASSOCIATES LLP
CHARTERED
ACCOUNTANTS
Firm Registration No:
004915S/S200036



Place: Chennai
Date: 02/11/2018

K.PARTHASARATHY
Partner

Membership No: 018394

Caplin Q2 FY19 Operating income at Rs. 1,559 mn, PAT at Rs. 435 mn

Sets up R&D facility for Intermediates & API.

Chennai, India, November 2nd, 2018 – Caplin Laboratories Ltd (NSE: CAPLIPOINT; BSE Code: 524742), one of the fastest growing pharmaceutical companies in India today announced financial results for the Second quarter (Q2FY19) ended September 30th, 2018.

Financial Highlights

Consolidated Q2FY19 (Y-o-Y)

- Operating Revenue was Rs. 1,559 mn as compared to Rs. 1,313 mn, an increase of **18.7%**
- Total Revenue was Rs. 1,628 mn as compared to Rs. 1,349 mn, an increase of **20.7%**
- EBITDA stood at Rs. 628 mn as compared to Rs. 529 mn
- EBITDA Margin stood at **38.6%**
- Net profit stood at Rs. 435 mn as compared to Rs. 355 mn
- Basic EPS stood at Rs.6.21 as against Rs. 4.71

Consolidated H1FY19 (Y-o-Y)

- Operating Revenue was Rs. 3,023 mn as compared to Rs. 2,548 mn, an increase of **18.6%**
- Total Revenue was Rs. 3,109 mn as compared to Rs. 2,623 mn, an increase of **18.5%**
- EBITDA stood at Rs. 1,174 mn as compared to Rs. 1,027 mn
- EBITDA Margin stood at **37.8%**
- Net profit stood at Rs. 809 mn as compared to Rs. 719 mn
- Basic EPS stood at Rs.11.16 as against Rs. 9.53

in Rs. millions

	Q2FY19	Q1FY19	QoQ	Q2FY18	YoY	H1FY19	H1FY18	YoY
Operating Revenue	1,559	1,465	6.4%	1,313	18.7%	3,023	2,548	18.6%
Total Revenue	1,628	1,480	10.0%	1,349	20.7%	3,109	2,623	18.5%
EBITDA	628	546	15.0%	529	18.7%	1,174	1,027	14.3%
EBITDA%	38.6%	36.9%		39.2%		37.8%	39.2%	
PAT	435	374	16.3%	355	22.5%	809	719	12.5%
EPS (Rs)	6.21	4.95	25.5%	4.71	31.8%	11.16	9.53	17.1%

Commenting on the performance Dr. Sridhar Ganesan, Managing Director of the Company said “We have shown a strong growth in revenues compared to same period of the previous financial year, and the same is reflected in our bottom line. Our EBITDA continues to remain at a very healthy level at close to 39%. Our entry into newer markets and newer segments in current markets have contributed to this growth.

We envision a strong closing over the next two quarters in terms of ANDA filings, and we’re hopeful of a couple of ANDA approvals too, which would give us some momentum with regards to revenues from US.



We've identified China as a high potential target for our growth trajectory and will continue focusing on this region, starting with supply of Intermediates and API for the short to mid-term."

Business Performance

Operational Highlights

- Expansion plans at Unit-1 in Pondicherry nearing completion. This includes addition of Injectable lines including Lyophilized Injectables and Pre-filled Syringes, for Emerging Markets.
- Due to increased demand from markets, capacity enhancement of Oral Solid Dosages and Softgel Capsules undertaken.
- State of the art R&D site established inside Chennai and expansion of the same ongoing, likely to be completed by the end of FY19.
- CRO wing of Caplin nearing completion, likely to be operational before end of FY2019.

Business Highlights

- Preparation underway to file products in **China** that have been filed/approved in the **US**.
- Facility identified and recruitments started for R&D of Intermediates and API, identifying **China** as a high potential market, in the wake of several API and Intermediates factories shut down in the country.
- Filed the 3rd ANDA under Caplin's name with US FDA. On target to file 4 more ANDAs before March 2019, bringing the total tally to 11 ANDAs (7 under Caplin and 4 with partners) filed from Unit-4. Two of these ANDAs have been approved already.
- US FDA audit completed with Zero 483s, for Unit-4. This is the second US FDA audit at this plant.
- EU-GMP renewal inspection successfully completed for Unit-4.

About Caplin Point Laboratories Ltd

Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Injectable & Ophthalmics facility that is approved by US FDA and EU-GMP.

Caplin Point has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging Company of 2018" by Economic Times Family Business Awards.



For details, feel free to contact:

Investor Relations Team at Caplin

Mr. Vinod Kumar (Company Secretary)

Tel: +91 44 24968000

investor@caplinpoint.net

Registered Office

Narbhavi No. 3, Lakshmanan Street,
T Nagar, Chennai, Tamil Nadu, 600017

Telephone: 044-28156653

CIN: L24231TN1990PLC019053

ISIN: INE475E01026

NSE Code: CAPLIPOINT

BSE CODE: 524742

Website: www.caplinpoint.net

